Psychosis and Co-Morbid Pituitary Adenoma (Prolactinoma): a Management Dilemma
This paper is a clinical as well as diagnostic
description of the presentation, investigation and pharmacological management
of an 18-year-old young woman with first episode of mental illness; and
recently diagnosed pituitary microadenoma (prolactin secreting type).
It brings to light the possible role of prolactin in
the development of psychosis, the treatment difficulties commonly encountered
in the choice of antipsychotics and / dopamine agonists and the need for an
interdisciplinary team approach when patients presents with such complex
S. and Barraclough, B. “Causes of the excess mortality of Schizophrenia”. British Journal of Psychiatry, vol. 177,
A. “Bromocriptine and psychosis- a literature review”, Psychiatric Quarterly,
Vol 66, No 1, pp. 87-93, 1995.
S.C., Chen, C.H., and Lu, M.L. “Cabergoline-induced psychotic exacerbation in
schizophrenia patients”. General Hospital
Psychiatry, Vol 30, No 4, pp. 378-380, 2008.
M.J., and Reveley, M.A. “Successful treatment of refractory schizophrenia with
combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary
microadenoma”. Journal of
psychopharmacology, Vol 19, 1, pp 97-104, 2005.
P.E., Parise, S.F., Kim, M.H. and O’Shaughnessy, R.O. “Bromocriptine associated
with symptoms exacerbation during narcoleptic’s treatment of Schizo- affective
Schizophrenia”. Journal of Clinical
Psychiatry, Vol. 43, No 6, pp 252-253, 1982.
L. “Current guidelines and their recommendations for prolactin monitoring in
psychosis”. Journal of psychopharmacology,
Vol. 22, No 2, pp 90-97, 2008.
L.M., Sheline, Y., Imai, K. et al., “Medical disorders among patients admitted
to a public sector psychiatric inpatient unit”. Psychiatric Services, Vol 53, No 12, pp 1623-1625, 2002.
J.A. “Dopamine partial agonist: a new class of antipsychotic”. CNS Drugs, Vol 18, No 4, pp. 251-267, 2004.
K., and Hulting, A.L. “Prolactin-secreting pituitary adenoma in neuroleptic
treated patients with psychotic disorder”. European
Archives of psychiatry and clinical neuroscience, Vol. 250, No 1, pp.6 –
10. Melmed S, Kleinberg D. “Anterior
pituitary”. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams
Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier;
2008: Chapt 8.
11. Molitch ME. “Anterior Pituitary”.
In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia,
Pa: Saunders Elsevier; 2011: Chapt 231.
J.K. and Sarino, W.A. “Effect of Risperidone on prolactinoma growth in a
psychotic woman”. Psychosomatic medicine,
Vol 62, No 5, pp. 736-738, 2000.
C. and Beer, D. “Physical health problems in Schizophrenia and other serious
mental illness’. Journal of Psychiatry
Intensive Care, Vol. 3, pp 101-111, 2007.
M. and During, K. “Treatment complexities of a young woman suffering psychosis
and pituitary Adenoma”. Case report in
psychiatry, Vol. 2011.
R., Bergsneider, M. and Lacono, R.P “Acute psychosis in a woman with a
protactinoma” International Journal of
Neuroscience, Vol. 37, no 3-4 pp. 187-190, 1987.
J. and Jones, I. “Clinical questions and uncertainty-prolactin measurement in
patients with schizophrenia and bipolar disorder”. Journal of psychopharmacology, Vol 22 No 2; pp 82-89, 2008.
Federation for Mental Health “the impact of physical health problem for person
with severe mental health disorder “in the Relationship between physical and
mental health: Co-occurring Disorders,